August 2026– date –
-
Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio; Curium Announces ~$8 Billion Acquisition of Lantheum
Pharmaceutical Technology Global Overview Indian pharmaceutical services group Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio, a Hyderabad-based CDMO specializing in vaccines and biopharmaceuticals, strengthening its... -
Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal
Herbert Smith Freehills Kramer Global Overview The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun P... -
Caltech Unveils ‘BrainCAB’ Molecular Shuttle for Enhanced Blood-Brain Barrier Drug Delivery Targeting Carbonic Anhydrase IV
Caltech News USA Overview Caltech researchers have developed 'BrainCAB,' a novel molecular shuttle that efficiently crosses the blood-brain barrier (BBB) to deliver drugs to the brain. This technology utilizes a small molecule shuttle th... -
A*STAR Successfully Identifies Bispecific Antibody Stability Risks: Enhancing Manufacturability and Robustness of Next-Gen Biologics
A*STAR Singapore Overview Researchers at A*STAR's Bioprocessing Technology Institute (BTI) in Singapore have successfully identified 'labile regions' within bispecific antibodies (BsAbs) that compromise their manufacturing and stability.... -
GLP-1 Receptor Agonist Mechanism of Action: A Comprehensive Approach to Glycemic Control, Weight Loss, and Metabolic Health
(Document via Google Search) Overview GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs that mimic incretin action to manage blood sugar and promote weight loss. They stimulate insulin secretion, suppress glucagon production, and ... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
Scientists Discover POLDIP2 as ‘Molecular Glue’ Controlling Heme, Unlocking Insights for Rare Disease Treatment
YouTube (The Deep Dive Lab) USA Overview Scientists have discovered a novel 'molecular glue' controlling heme production, the essential oxygen-carrying molecule. The mitochondrial protein POLDIP2 utilizes heme as a molecular glue to bind... -
NJ Cancer Care Offers New Hope for Refractory Cancer Patients with Bispecific Antibody Therapy
NJ Cancer Care USA Overview NJ Cancer Care highlights bispecific antibody therapy as a groundbreaking treatment utilizing the patient's immune system to target and destroy cancer cells, offering new hope for those unresponsive to standar... -
Eli Lilly’s Oral GLP-1 Agonist ‘Foundayo (orforglipron)’ Receives FDA Approval for Obesity and Overweight Treatment
Drugs.com USA Overview Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, has received FDA approval for adults with obesity or certain weight-related conditions. This small-molecule, non-peptide GLP-1 receptor... -
FDA Grants Fast Track Designation to Erasca’s Oral Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
OncLive USA Overview Erasca's oral pan-RAS molecular glue, ERAS-0015, has received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma. The drug demonstrated promising initial activity in a Phase 1 study for KRAS G12-muta...
